Defective CFTR leads to aberrant β-catenin activation and kidney fibrosis

Jie Ting Zhang^{1,3*}, Yan Wang^{1,3*}, Jun Jiang Chen¹, Xiao Hu Zhang¹, Jian Da Dong^{1,5}, Lai Ling Tsang¹, Xiao Ru Huang², Zhiming Cai⁴, Hui Yao Lan², Xiao Hua Jiang^{1,3#}, Hsiao Chang Chan^{1,3 #}

¹Epithelial Cell Biology Research Center, Key Laboratory for Regenerative Medicine of Ministry of Education of China, School of Biomedical Sciences, ²Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

³School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen 518057, China.

⁴Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.

⁵ Key Laboratory of Reproduction and Genetic of Ningxia Hui Autonomous Region, Key Laboratory of Fertility Preservation and Maintenance of Ningxia Medical University and Ministry of Education of China, Yinchuan, People's Republic of China

Supplementary information:

Supplementary Figure legends

Supplementary Figure 1. Suppression of CFTR during EMT is not related to TGF- β /Smads signaling. (a) Immunofluorescent staining shows that CFTR protein is expressed at cell-cell adhesion and cytoplasm in tubular epithelium in normal human kidney, whereas significantly decreased in fibrotic kidney tissue (n=2), scale bar=50µm.

(b) MDCK cells were treated with 2ng/ml TGF- β_1 for 3 days. Western blot analysis shows that while TGF- β_1 significantly induces EMT markers, it does not have any effect on CFTR expression in MDCK cells (Full-length blot is shown in supplementary figure S7m); (c) Immunofluorescent staining shows that the expression of CFTR is decreased, whereas the expression of HIF-1 α is significantly induced in UUO kidney in both wild type and Smad3 knockout (*smad3 KO*) mice; (d) Western blot analysis shows that CFTR inhibitors have no effect on the expression of phosphorylated-Smad2 in MDCK cells (Full-length blot is shown in supplementary figure S7n).

Supplementary Figure 2. Dysregulation of CFTR induces EMT in kidney epithelial cells. (a) Phase-contrast photomicrographs of MDCK cells treated with 10µM CFTRinh-172 (inh172) or 5µM GlyH101 for 48 hours; (b) Western blot analysis showing increased Vimentin expression and decreased Occludin expression in MDCK cells treated with different concentration of GlyH101 for 48hours; quantification analysis is shown in the lower panel, *p<0.05, **p<0.01. (Full-length blot is shown in supplementary figure S70.); (c) Quantification of western blot showing significantly reduced CFTR expression in MDCK cells 48 hours post transfection with CFTR miRNA, *p<0.05; (d) Real time-PCR showing significantly reduced CFTR expression by ribozyme (rib) -mediated CFTR knockdown in HK-2 cells; (e) Western blot showing decreased E-cadherin expression and increased SMA expression in CFTR knockdown HK2 cells compared to control cells; quantification analysis is shown in the lower panel, *p<0.05. (Full-length blot is shown in supplementary figure S7p); (f) MTS assay shows no significant changes in cell proliferation in CFTR knockdown HK-2 cells compared to control cells; (g) Wound-healing migration assay showing enhanced cell migration in CFTR knockdown HK-2 cells compared to control cells.

Supplementary Figure 3. Focused PCR analysis showing upregulated mRNA expression of various EMT and migration-associated genes in CFTR knockdown HK-2 cells. A human fibrosis-focused PCR array was used to analyze the expression of a panel of genes involved in fibrosis. Expression levels of 19 genes show more than 2-folds change in CFTR knockdown HK-2 cells compared to control cells. (p<0.05)

Supplementary Figure 4. **CFTR** regulates **B**-catenin signaling. **(a)** Immunofluorescent staining showing the nuclear translocation of β -catenin in CFTR inhibitor-treated MDCK cells; (b) Western blot showing overexpression of CFTR in HK-2 cells (Full-length blot is shown in supplementary figure S7q); (c) Western blot showing knockdown of CFTR in HK-2 cells does not affect the expression of β-catenin destruction complex proteins (Full-length blot is shown in supplementary figure S7r.); (d) HK-2 cells were treated with 10μ M β -catenin activator, CHIR 99021, for 48 hours. Western blot showing activation of β -catenin promotes EMT (Full-length blot is shown in supplementary figure S7s); (e) Western blot using primary antibody against GFP, showing the expression level of wild type CFTR (CFTRwt) and CFTR with deletion of the PDZ binding domain (CFTR delPDZ) (Full-length blot is shown in supplementary figure S7t).

Supplementary Figure 5. Defective CFTR aggravates the development of renal fibrosis. (a) Western blot showing the expression levels of CFTR in WT and Δ F508 mice (Full-length blot is shown in supplementary figure S7u); (b) PCR result showing the genotype of WT, Δ F508 hetero and Δ F508 homo mice. (c) H&E staining showing more inflammatory cell invasion in Δ F508 CFTR mice after UUO procedure compare

to wild type mice. Note the accumulation of inflammatory cells (arrow) in the UUO kidneys at 7 days after ligation; (c) Masson's trichrome stain showing more interstitial collagen expression in Δ F508 CFTR mice after UUO procedure compared to wild type mice.

Supplementary Figure 6. Forced expression of CFTR downregulates β -catenin target in UUO model. (a) Real time-PCR analysis showing the significantly overexpression of CFTR in peGFP-CFTR overexpression kidneys compared to peGFP-C3 control kidneys. *p<0.05, quantification analysis represents data from 9 control and 10 CFTR overexpressed UUO kidneys; (b) Representative western blot showing reduced Axin2 expression in CFTR overexpressed UUO kidneys compared to control kidneys. (Full-length blot is shown in supplementary figure S7v.) Quantification data is shown in the right panel (n=6-7).

Supplementary Figure 7. Full-length gel images of western blots.



d



















Zhang JT et al., Supplementary Figure 7



Zhang JT et al., Supplementary Figure 7





Supplementary Table1 Primer information (Human)

Gene		Primer sequence (5'-3')	size	Tm
CFTR	forward	GTGTGATTCCACCTTCTCCAA	149bp	60°C
	reverse	GCCTGGCACCATTAAAGAAA		
Axin2	forward	CTGGTGCAAAGACATAGCCA	103bp	60°C
	reverse	AGTGTGAGGTCCACGGAAAC		
C-Met	forward	TGTTCGATATTCATCACGGC	94bp	60°C
	reverse	GCATTTTTACGGACCCAATC		
MMP7	forward	GCATCTCCTTGAGTTTGGCT	103bp	60°C
	reverse	GAGCTACAGTGGGAACAGGC		
GAPDH	forward	AGGGTCATCATCTCTGCC	245bp	60°C
	reverse	CCATCACGCCACAGTTTC		

Supplementary Table2 Primer information (Mouse)

Gene		Primer sequence (5'-3')	size	Tm
A.vin2	forward	ACTGACCGACGATTCCATGT	96bp	60°C
Axin2	reverse	TGCATCTCTCTCTGGAGCTG		
	forward	GGGACACAGCTTTCACCCTA	104bp	60°C
c-jun	reverse	GAAAAGTAGCCCCCAACCTC		
10.07	forward	GCATTTCCTTGAGGTTGTCC	102bp	60°C
MMP/	reverse	CACATCAGTGGGAACAGGC		
	forward	GGGATCCTGACGCTGAAGTA	147bp	60°C
a-SMA	reverse	GTTCAGTGGTGCCTCTGTCA		
C-11 A 1	forward	ACATGTTCAGCTTTGTGGACC	110bp	60°C
Collai	reverse	TAGGCCATTGTGTATGCAGC		
ENI	forward	ACCTCTGCAGACCTACCCAG	120bp	60°C
FN	reverse	TTGGTGATGTGTGAAGGCTC		
CADDU	forward	AACGACCCCTTCATTGAC	190bp	60°C
GAPDH	reverse	TCCACGACATACTCAGCAC		
OFTD	TTCAAGCCCAAGCTTTCGCGAG		WT:430 bp	
(Genotype)	CTCCCTTCTTCTAGTCACAACCG		Hetero:430+300 bp	
	CAT	ATCTTGATAGAGCCACGGTGC Homo:300 b		300 bp